BioNTech SE
BNTX
$101.81
$3.053.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -20.33% | 40.44% | -24.11% | -85.13% | -63.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.33% | 40.44% | -24.11% | -85.13% | -63.58% |
| Cost of Revenue | 34.62% | 11.68% | -63.70% | -37.68% | 2.84% |
| Gross Profit | -27.90% | 46.78% | 1,319.37% | -88.99% | -66.55% |
| SG&A Expenses | -8.08% | -0.97% | 31.80% | 8.25% | 11.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 110.26% | 1,070.59% | 1,599.24% | 84.50% | -115.54% |
| Total Operating Expenses | 115.70% | 46.66% | 64.15% | 40.26% | -19.49% |
| Operating Income | -84.39% | -59.71% | -94.41% | -165.42% | -71.04% |
| Income Before Tax | -55.03% | -29.51% | -93.30% | -147.46% | -77.97% |
| Income Tax Expenses | -79.89% | -159.58% | 100.89% | -108.23% | -75.80% |
| Earnings from Continuing Operations | -43.89% | 24.59% | -319.53% | -163.51% | -78.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.89% | 24.59% | -319.53% | -163.51% | -78.83% |
| EBIT | -84.39% | -59.71% | -94.41% | -165.42% | -71.04% |
| EBITDA | -73.48% | -29.61% | -97.18% | -158.09% | -70.21% |
| EPS Basic | -44.02% | 23.63% | -320.57% | -164.06% | -78.54% |
| Normalized Basic EPS | -51.71% | -13.95% | -89.91% | -144.33% | -77.25% |
| EPS Diluted | -43.76% | 23.96% | -320.57% | -164.69% | -78.42% |
| Normalized Diluted EPS | -51.45% | -13.71% | -89.91% | -144.77% | -77.07% |
| Average Basic Shares Outstanding | 0.23% | 0.79% | -0.25% | -0.85% | -1.31% |
| Average Diluted Shares Outstanding | -0.30% | 0.51% | -0.25% | -1.81% | -2.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |